Developer docs
API playgroundTry for free, no card

Search company profiles

Modalis Therapeutics

Full company profile

uuid0004dyj

Namestring
Modalis Therapeutics
Legal namestring
Modalis Therapeutics Corporation
Websiteurl
modalistx.com
Company typeenum
Public
Founded yearint
2016
Descriptiontext

Modalis Therapeutics Corporation is a clinical-stage Japanese biotechnology company developing single-dose gene therapies for rare genetic diseases using its proprietary CRISPR-GNDM® epigenome editing platform. Founded in January 2016 in Tokyo (originally as EdiGene Corporation, renamed Modalis in August 2019), the company is publicly listed on the Tokyo Stock Exchange Growth Market under ticker 4883 since 2020, with corporate headquarters in Tokyo and R&D operations at a Greater Boston facility in Waltham, Massachusetts (relocated from Cambridge in October 2021). Modalis targets ultra-rare genetic disorders across muscular dystrophies (LAMA2-CMD, DMD, DM1, FSHD), cardiomyopathy (DCM), and central nervous system conditions (Tauopathy, Angelman Syndrome, Dravet Syndrome), with MDL-101 for LAMA2-CMD as the lead IND-enabling program.

The core technology, CRISPR-GNDM®, combines nuclease-deficient Cas9 (dCas9) with proprietary epigenome editors and guide RNA, packaged into AAV vectors for delivery. The platform modulates gene expression without altering DNA sequence or creating double-strand breaks, which Modalis positions as a safety advantage over conventional CRISPR nucleases. The company has also developed an engineered muscle-selective AAV capsid with greater than 10-fold improved tropism and a muscle-specific promoter, providing dual-layer tissue selectivity for muscle-targeted programs. Modalis licenses foundational IP from the University of Tokyo (engineered Cas9, 2017) and Editas Medicine (CRISPR/Cas9 patents, 2020), and has built a pipeline of eight named drug candidates leveraging the platform.

Modalis operates a hybrid business model: in-house pipeline assets are advanced to a defined preclinical or IND-enabling stage using internal funding, then out-licensed to pharmaceutical partners for late-stage development, manufacturing scale-up, and commercialization, generating revenue through upfront payments, development and sales milestones, and royalties. Key partnerships include two license agreements with Astellas Pharma (2019) and a collaboration with Eisai (2019). The company has FDA Rare Pediatric Disease and Orphan Drug designations for MDL-101 and conducts clinical manufacturing through CDMOs while bringing select CMC and clinical functions in-house. The acquired entity Air Flow (September 2024) extends capabilities beyond the core platform. End customers are patient populations with rare genetic conditions, served indirectly through licensed pharmaceutical partners rather than direct sales.

Short descriptiontext

Modalis Therapeutics is a clinical-stage Japanese biotech developing single-dose gene therapies using its proprietary CRISPR-GNDM® epigenome editing platform to treat rare genetic muscular, cardiac, and CNS disorders, licensing programs to pharmaceutical partners such as Astellas and Eisai for late-stage development and commercialization.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
epigenome editing therapeutics, CRISPR-based gene therapy, rare disease treatments, AAV gene therapy development, biopharmaceutical licensing
Industry6 codes
PRIMARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Gene Therapy Pharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing and milestone payments
TypeLicensing Royalties
Description

Revenue from upfront payments at contract signing, development milestones as pipeline progresses, and royalties on sales after product launch. Partnering provides short-term licensing fees swapped for long-term profits from future product sales. Revenue recognized when contracts signed or when stipulated conditions are met.

modalistx.com
2Clinical/sales milestones
TypeTransaction Fee
Description

Revenue from achieving clinical trial milestones and sales milestones if specific sales targets are met under licensing agreements.

modalistx.com
3Royalty income
TypeLicensing Royalties
Description

Ongoing royalties from product sales after commercialization under licensing agreements.

modalistx.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Modalis Therapeutics develops AAV-delivered gene therapy drug candidates using its proprietary CRISPR-GNDM® epigenome editing platform, which regulates gene expression without cutting DNA. The company focuses on rare genetic diseases including LAMA2-CMD, FSHD, and DM1, advancing a pipeline of drug candidates such as MDL-101, MDL-201, and MDL-202 through in-house development and partner licensing arrangements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • CRISPR-GNDM demonstrated 1) single-dose administration, 2) long-lasting effect, and 3) fundamental disease improvement in animal testing
+2 more records
Product overview1 text field

Modalis Therapeutics is a biotech company developing a pipeline of gene therapy drug candidates using its proprietary CRISPR-GNDM® epigenome editing platform. The company's lead program MDL-101 targets LAMA2-CMD, with additional candidates including MDL-202 (DM1), MDL-201 (DMD), MDL-103 (FSHD), MDL-105 (DCM), MDL-104 (Tauopathy), MDL-206 (Angelman Syndrome), and MDL-207 (Dravet Syndrome). The CRISPR-GNDM® platform enables targeted gene expression modulation via AAV-delivered epigenome editors without altering DNA sequences.

Product and service4 records
1MDL-101
CategoryGene Therapy Pharmaceutical
Description

AAV-delivered CRISPR-GNDM® based gene therapy candidate for LAMA2-related congenital muscular dystrophy (LAMA2-CMD), designed to upregulate compensatory LAMA1 expression to address the genetic deficiency in skeletal and cardiac muscle. Aimed at patients with this rare neuromuscular disease.

2MDL-201
CategoryGene Therapy Pharmaceutical
Description

AAV-delivered CRISPR-GNDM® based therapy candidate for facioscapulohumeral muscular dystrophy (FSHD), designed to suppress DUX4 expression and address the underlying pathology of this rare neuromuscular disease.

3MDL-202
CategoryGene Therapy Pharmaceutical
Description

AAV-delivered CRISPR-GNDM® based therapy candidate for myotonic dystrophy type 1 (DM1), designed to address the CTG repeat expansion pathology underlying this rare neuromuscular disease.

4CRISPR-GNDM® Platform
CategoryPlatform Technology / Licensing Asset
Description

Proprietary CRISPR-GNDM® epigenome editing platform technology that uses nuclease-dead Cas9 (dCas9) fused to transcriptional modulators to upregulate or downregulate target genes without cutting DNA. Available for licensing and partnership arrangements with pharmaceutical and biotechnology companies seeking differentiated gene therapy modalities.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierMinorTypeOthersAnnounced on2026-05-14
Description

Swiss non-profit patient organization dedicated to LAMA2-related congenital muscular dystrophy. Provided donation to support continued R&D of MDL-101. Organization raises awareness and funding for LAMA2-RD research, supporting patient initiatives and international collaboration.

2LAMA2 Europe
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-01-20
Description

European patient organization network (Netherlands, Spain, France) focused on accelerating LAMA2-CMD treatment development. Published article about Modalis MDL-101 research following Human Gene Therapy publication. Provides patient community engagement and advocacy support.

modalistx.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-04-01
Description

License agreement for CRISPR/Cas9 foundational patents obtained April 2020. Non-exclusive license secures rights to foundational CRISPR IP in company's business areas, protecting business operations.

4Eisai Co., Ltd.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-11-01
Description

Collaboration agreement established November 2019 for application of epigenome editing technology to agreed-upon targets. Joint development using CRISPR-GNDM technology.

modalistx.com
5University of Tokyo
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2017-09-01
Description

Exclusive license for CRISPR technology from University of Tokyo obtained September 2017. Provides access to engineered Cas9 technology for epigenome editing applications.

modalistx.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-04-01
Description

Initial research collaboration formed April 2017; license agreement for genetic disorder established February 2019; second license agreement for additional genetic disorder established September 2019. Astellas provides funding and access to specific genetic targets for CRISPR-GNDM technology application.

7Cure CMD
Strategic tierMinorTypeGTM or Marketing Partner
Description

Congenital muscular dystrophy patient organization network. Collaboration for patient engagement and clinical trial readiness.

modalistx.com
Recent move19 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage AAV gene therapy company focused on rare CNS and neuromuscular diseases. Comparable business model to Modalis as a small-cap AAV gene therapy developer with multiple pipeline programs targeting rare monogenic disorders.

TypeEmerging player
Description

Clinical-stage company using in vivo base editing to treat cardiovascular diseases. Direct overlap with Modalis's MDL-105 (dilated cardiomyopathy) program in terms of indication, though using a different editing approach.

TypeBroad incumbent
Description

Commercial-stage gene therapy leader with approved AAV-delivered therapy (Elevidys) for Duchenne muscular dystrophy. Directly competes with Modalis's MDL-201 DMD program and other muscular dystrophy programs.

TypeBroad incumbent
Description

Pioneer in genome editing (zinc finger nucleases) and gene therapy with both in vivo AAV-delivered programs and ex vivo cell therapies. Competes in the same genetic disease space as Modalis but uses an older editing technology platform.

TypeDirect peer
Description

Clinical-stage company developing base editing and prime editing therapies for genetic diseases. Closely comparable to Modalis as a next-generation gene editing platform company pursuing rare monogenic diseases with proprietary editing chemistries.

TypeDirect peer
Description

Clinical-stage CRISPR/Cas9-based gene editing company with in vivo and ex vivo programs. Both companies use CRISPR-based platforms delivered via AAV (or LNP) to address genetic diseases, making Intellia a close technological peer despite differing editing mechanisms.

TypeEmerging player
Description

Clinical-stage company developing prime editing technology for precise genome editing. Conceptually similar to Modalis in pursuing next-generation editing approaches, though prime editing uses a different mechanism than epigenome editing.

TypeBroad incumbent
Description

Commercial-stage rare disease company with gene therapy programs for DMD and CNS disorders. Competitor in overlapping indications (DMD, Dravet Syndrome via partner programs) with broader therapeutic portfolio.

TypeDirect peer
Description

Clinical-stage CRISPR/Cas9 gene editing company developing in vivo and ex vivo gene therapies. Modalis licenses foundational IP from Editas and operates in overlapping genome editing space, though Modalis focuses specifically on epigenome editing rather than nuclease-based editing.

TypeDirect peer
Description

Pioneer in CRISPR/Cas9 therapeutics with approved CASGEVY therapy (via Vertex partnership) for sickle cell disease and beta-thalassemia. Operates in the same gene editing category as Modalis with both in vivo and ex vivo approaches.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Modalis Therapeutics

Gene Therapy Pharmaceuticalsmodalistx.com

Modalis Therapeutics is a clinical-stage Japanese biotech developing single-dose gene therapies using its proprietary CRISPR-GNDM® epigenome editing platform to treat rare genetic muscular, cardiac, and CNS disorders, licensing programs to pharmaceutical partners such as Astellas and Eisai for late-stage development and commercialization.

What Modalis Therapeutics does

Modalis Therapeutics Corporation is a clinical-stage Japanese biotechnology company developing single-dose gene therapies for rare genetic diseases using its proprietary CRISPR-GNDM® epigenome editing platform. Founded in January 2016 in Tokyo (originally as EdiGene Corporation, renamed Modalis in August 2019), the company is publicly listed on the Tokyo Stock Exchange Growth Market under ticker 4883 since 2020, with corporate headquarters in Tokyo and R&D operations at a Greater Boston facility in Waltham, Massachusetts (relocated from Cambridge in October 2021). Modalis targets ultra-rare genetic disorders across muscular dystrophies (LAMA2-CMD, DMD, DM1, FSHD), cardiomyopathy (DCM), and central nervous system conditions (Tauopathy, Angelman Syndrome, Dravet Syndrome), with MDL-101 for LAMA2-CMD as the lead IND-enabling program.

The core technology, CRISPR-GNDM®, combines nuclease-deficient Cas9 (dCas9) with proprietary epigenome editors and guide RNA, packaged into AAV vectors for delivery. The platform modulates gene expression without altering DNA sequence or creating double-strand breaks, which Modalis positions as a safety advantage over conventional CRISPR nucleases. The company has also developed an engineered muscle-selective AAV capsid with greater than 10-fold improved tropism and a muscle-specific promoter, providing dual-layer tissue selectivity for muscle-targeted programs. Modalis licenses foundational IP from the University of Tokyo (engineered Cas9, 2017) and Editas Medicine (CRISPR/Cas9 patents, 2020), and has built a pipeline of eight named drug candidates leveraging the platform.

Modalis operates a hybrid business model: in-house pipeline assets are advanced to a defined preclinical or IND-enabling stage using internal funding, then out-licensed to pharmaceutical partners for late-stage development, manufacturing scale-up, and commercialization, generating revenue through upfront payments, development and sales milestones, and royalties. Key partnerships include two license agreements with Astellas Pharma (2019) and a collaboration with Eisai (2019). The company has FDA Rare Pediatric Disease and Orphan Drug designations for MDL-101 and conducts clinical manufacturing through CDMOs while bringing select CMC and clinical functions in-house. The acquired entity Air Flow (September 2024) extends capabilities beyond the core platform. End customers are patient populations with rare genetic conditions, served indirectly through licensed pharmaceutical partners rather than direct sales.

Modalis Therapeutics firmographics

Firmographics
Name
Modalis Therapeutics
Legal name
Modalis Therapeutics Corporation
Website
https://modalistx.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Modalis Therapeutics is a clinical-stage Japanese biotech developing single-dose gene therapies using its proprietary CRISPR-GNDM® epigenome editing platform to treat rare genetic muscular, cardiac, and CNS disorders, licensing programs to pharmaceutical partners such as Astellas and Eisai for late-stage development and commercialization.
Ownership category
akta.pro rank

Modalis Therapeutics industry classification

Industry
Product category
Gene Therapy Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Epigenome editing therapeutics
  • CRISPR-based gene therapy
  • Rare disease treatments
  • AAV gene therapy development
  • Biopharmaceutical licensing

Where Modalis Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Modalis Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Licensing and milestone payments: Revenue from upfront payments at contract signing, development milestones as pipeline progresses, and royalties on sales after product launch. Partnering provides short-term licensing fees swapped for long-term profits from future product sales. Revenue recognized when contracts signed or when stipulated conditions are met.
  2. Clinical/sales milestones: Revenue from achieving clinical trial milestones and sales milestones if specific sales targets are met under licensing agreements.
  3. Royalty income: Ongoing royalties from product sales after commercialization under licensing agreements.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Modalis Therapeutics product offering

Product offering

Core offering

Modalis Therapeutics develops AAV-delivered gene therapy drug candidates using its proprietary CRISPR-GNDM® epigenome editing platform, which regulates gene expression without cutting DNA. The company focuses on rare genetic diseases including LAMA2-CMD, FSHD, and DM1, advancing a pipeline of drug candidates such as MDL-101, MDL-201, and MDL-202 through in-house development and partner licensing arrangements.

Product overview

Modalis Therapeutics is a biotech company developing a pipeline of gene therapy drug candidates using its proprietary CRISPR-GNDM® epigenome editing platform. The company's lead program MDL-101 targets LAMA2-CMD, with additional candidates including MDL-202 (DM1), MDL-201 (DMD), MDL-103 (FSHD), MDL-105 (DCM), MDL-104 (Tauopathy), MDL-206 (Angelman Syndrome), and MDL-207 (Dravet Syndrome). The CRISPR-GNDM® platform enables targeted gene expression modulation via AAV-delivered epigenome editors without altering DNA sequences.

Differentiator

Problem solved

Functional benefit

Products and services

  • MDL-101 AAV-delivered CRISPR-GNDM® based gene therapy candidate for LAMA2-related congenital muscular dystrophy (LAMA2-CMD), designed to upregulate compensatory LAMA1 expression to address the genetic deficiency in skeletal and cardiac muscle. Aimed at patients with this rare neuromuscular disease.
  • MDL-201 AAV-delivered CRISPR-GNDM® based therapy candidate for facioscapulohumeral muscular dystrophy (FSHD), designed to suppress DUX4 expression and address the underlying pathology of this rare neuromuscular disease.
  • MDL-202 AAV-delivered CRISPR-GNDM® based therapy candidate for myotonic dystrophy type 1 (DM1), designed to address the CTG repeat expansion pathology underlying this rare neuromuscular disease.
  • CRISPR-GNDM® Platform Proprietary CRISPR-GNDM® epigenome editing platform technology that uses nuclease-dead Cas9 (dCas9) fused to transcriptional modulators to upregulate or downregulate target genes without cutting DNA. Available for licensing and partnership arrangements with pharmaceutical and biotechnology companies seeking differentiated gene therapy modalities.

Quantifiable outcome

  • CRISPR-GNDM demonstrated 1) single-dose administration, 2) long-lasting effect, and 3) fundamental disease improvement in animal testing
  • +2 more outcomes

Companies that use Modalis Therapeutics

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Modalis Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Modalis Therapeutics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered minor and core.

  • Emily's Future is NowminorOthers · 14 May 2026Swiss non-profit patient organization dedicated to LAMA2-related congenital muscular dystrophy. Provided donation to support continued R&D of MDL-101. Organization raises awareness and funding for LAMA2-RD research, supporting patient initiatives and international collaboration.
  • LAMA2 EuropeminorGTM or Marketing Partner · 20 January 2026European patient organization network (Netherlands, Spain, France) focused on accelerating LAMA2-CMD treatment development. Published article about Modalis MDL-101 research following Human Gene Therapy publication. Provides patient community engagement and advocacy support.
  • Editas Medicine, Inc.coreTechnology or Integration · 1 April 2020License agreement for CRISPR/Cas9 foundational patents obtained April 2020. Non-exclusive license secures rights to foundational CRISPR IP in company's business areas, protecting business operations.
  • Eisai Co., Ltd.coreStrategic or Co-development Partner · 1 November 2019Collaboration agreement established November 2019 for application of epigenome editing technology to agreed-upon targets. Joint development using CRISPR-GNDM technology.
  • University of TokyocoreTechnology or Integration · 1 September 2017Exclusive license for CRISPR technology from University of Tokyo obtained September 2017. Provides access to engineered Cas9 technology for epigenome editing applications.
  • Astellas Pharma Inc.coreStrategic or Co-development Partner · 1 April 2017Initial research collaboration formed April 2017; license agreement for genetic disorder established February 2019; second license agreement for additional genetic disorder established September 2019. Astellas provides funding and access to specific genetic targets for CRISPR-GNDM technology application.
  • Cure CMDminorGTM or Marketing PartnerCongenital muscular dystrophy patient organization network. Collaboration for patient engagement and clinical trial readiness.

Scale indicators6 records

Recent moves19 records

Expansion highlights6 records

Modalis Therapeutics competitors and assessment

Company assessment

Emerging players

  • Taysha Gene Therapies: Clinical-stage AAV gene therapy company focused on rare CNS and neuromuscular diseases. Comparable business model to Modalis as a small-cap AAV gene therapy developer with multiple pipeline programs targeting rare monogenic disorders.
  • Verve Therapeutics: Clinical-stage company using in vivo base editing to treat cardiovascular diseases. Direct overlap with Modalis's MDL-105 (dilated cardiomyopathy) program in terms of indication, though using a different editing approach.
  • Prime Medicine: Clinical-stage company developing prime editing technology for precise genome editing. Conceptually similar to Modalis in pursuing next-generation editing approaches, though prime editing uses a different mechanism than epigenome editing.

Broad incumbents

  • Sarepta Therapeutics: Commercial-stage gene therapy leader with approved AAV-delivered therapy (Elevidys) for Duchenne muscular dystrophy. Directly competes with Modalis's MDL-201 DMD program and other muscular dystrophy programs.
  • Sangamo Therapeutics: Pioneer in genome editing (zinc finger nucleases) and gene therapy with both in vivo AAV-delivered programs and ex vivo cell therapies. Competes in the same genetic disease space as Modalis but uses an older editing technology platform.
  • PTC Therapeutics: Commercial-stage rare disease company with gene therapy programs for DMD and CNS disorders. Competitor in overlapping indications (DMD, Dravet Syndrome via partner programs) with broader therapeutic portfolio.

Direct peers

  • Beam Therapeutics: Clinical-stage company developing base editing and prime editing therapies for genetic diseases. Closely comparable to Modalis as a next-generation gene editing platform company pursuing rare monogenic diseases with proprietary editing chemistries.
  • Intellia Therapeutics: Clinical-stage CRISPR/Cas9-based gene editing company with in vivo and ex vivo programs. Both companies use CRISPR-based platforms delivered via AAV (or LNP) to address genetic diseases, making Intellia a close technological peer despite differing editing mechanisms.
  • Editas Medicine: Clinical-stage CRISPR/Cas9 gene editing company developing in vivo and ex vivo gene therapies. Modalis licenses foundational IP from Editas and operates in overlapping genome editing space, though Modalis focuses specifically on epigenome editing rather than nuclease-based editing.
  • CRISPR Therapeutics: Pioneer in CRISPR/Cas9 therapeutics with approved CASGEVY therapy (via Vertex partnership) for sickle cell disease and beta-thalassemia. Operates in the same gene editing category as Modalis with both in vivo and ex vivo approaches.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Modalis Therapeutics social profiles

Digital presence

Modalis Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Modalis Therapeutics leadership team

Management profile

Number of profiles

Modalis Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Modalis Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Modalis Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Modalis Therapeutics

What does Modalis Therapeutics do?

Modalis Therapeutics develops AAV-delivered gene therapy drug candidates using its proprietary CRISPR-GNDM® epigenome editing platform, which regulates gene expression without cutting DNA. The company focuses on rare genetic diseases including LAMA2-CMD, FSHD, and DM1, advancing a pipeline of drug candidates such as MDL-101, MDL-201, and MDL-202 through in-house development and partner licensing arrangements.

Is Modalis Therapeutics a public or private company?

Modalis Therapeutics is a public company. It is classified as unknown and is currently operating.

When was Modalis Therapeutics founded?

Modalis Therapeutics was founded in 2016. It employs 11 to 50 people.

Where is Modalis Therapeutics based?

Modalis Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does Modalis Therapeutics make money?

Three revenue lines are on record. Licensing and milestone payments are the primary driver. The others are clinical/sales milestones and royalty income.

Who are Modalis Therapeutics's main competitors?

Emerging players on record are Taysha Gene Therapies, Verve Therapeutics and Prime Medicine. Broad incumbents are Sarepta Therapeutics, Sangamo Therapeutics and PTC Therapeutics. Direct peers are Beam Therapeutics, Intellia Therapeutics, Editas Medicine and CRISPR Therapeutics.

Does Modalis Therapeutics have an API?

No public API is recorded for Modalis Therapeutics.

What industry is Modalis Therapeutics in?

Modalis Therapeutics's product category is Gene Therapy Pharmaceuticals. Its primary akta.pro industry code is HLAAACAD, Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo), with a secondary code of HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StHere's Why We're Watching Modalis Therapeutics' (TSE:4883) Cash Burn SituationModalis Therapeutics burned JP¥1.9b last year, giving a 15-month cash runway from September 2026. Its cash burn rose 7.8% annually, and the burn represented 58% of its JP¥3.3b market cap, raising concerns about future capital raising.BioSpaceExegenesis Bio and Modalis Collaborate to Advance MDL-201 for Duchenne Muscular DystrophyExegenesis Bio and Modalis signed a research collaboration and license agreement to advance MDL-201, a Duchenne muscular dystrophy therapy using Modalis' CRISPR-GNDM epigenome editing and Exegenesis' EMC181 AAV capsid. The agreement, effective September 14, 2026, aims to accelerate development toward clinical application. Modalis expects the financial impact to be immaterial for the current fiscal year.MorningstarExegenesis Bio and Modalis Collaborate to Advance MDL-201 for Duchenne Muscular DystrophyExegenesis Bio and Modalis signed a research collaboration and license agreement to advance MDL-201, a Duchenne muscular dystrophy therapy using Modalis' CRISPR-GNDM epigenome editing and Exegenesis' EMC181 AAV capsid. The agreement becomes effective September 14, 2026, aiming to accelerate the therapy toward clinical application.CRISPR MedicineNews: Gene Editing for Muscular Dystrophies: Where Do We Stand?HuidaGene Therapeutics presented preliminary clinical data at the CRISPR Medicine Conference 2025 showing its HG302 gene-editing therapy for Duchenne muscular dystrophy (DMD) demonstrated safety and positive functional improvements in the first two patients dosed in the Phase I MUSCLE trial, three months after low-dose injection. Epicrispr Biotechnologies received FDA IND clearance in April 2025 to begin a Phase I trial of EPI-321 for facioscapulohumeral muscular dystrophy (FSHD) in New Zealand, while Modalis Therapeutics' MDL-101 for congenital muscular dystrophy received Rare Pediatric Disease and Orphan Disease designations from the FDA. The article reviews the broader landscape of gene-editing approaches for muscular dystrophies, noting that delivery challenges remain the primary obstacle for systemic editing of skeletal muscles.BioSpaceModalis Announces Publication in Human Gene Therapy of Study Demonstrating Efficient LAMA1 Gene Activation for the Treatment of LAMA2-CMDModalis Therapeutics Corporation announced the publication of its preclinical research study in the peer-reviewed journal Human Gene Therapy, demonstrating that its CRISPR-GNDM® epigenome editing technology can safely and robustly activate the LAMA1 gene as a therapeutic strategy for LAMA2-related congenital muscular dystrophy (LAMA2-CMD). The study showed marked improvement in survival and muscle function in mouse models, along with favorable safety and pharmacodynamic profiles in non-human primates. The company is advancing its lead program MDL-101 with GLP toxicology studies and GMP manufacturing underway, planning to submit an investigational new drug application next year.BioCenturyPartnerships paved the way to a Tokyo IPO for ModalisModalis Therapeutics listed on the Tokyo Stock Exchange's Mothers on Aug. 3, raising ¥3.7 billion ($35.2 million) at ¥1,200 per share. Shares rose 203% to ¥2,435, giving a market cap of ¥98.9 billion ($929.5 million). The company cited profitability and pharma partnerships as key to its IPO.ModalistxModalis Therapeutics - Official SiteModalis Therapeutics, founded in 2016 as EdiGene, has a history of licensing CRISPR and genetic disorder technologies from partners like Astellas and Eisai. The company listed on the Tokyo Stock Exchange in October 2021 and has relocated its US subsidiary to a new facility.Fujifilm [Global]Fujifilm [Global]Fujifilm Group, established in 1934, operates in healthcare, electronics, innovation, and imaging. As of March 31, 2026, it reported revenue of 3,357.0 billion yen and employed 73,526 people. The company's healthcare business spans prevention, diagnosis, and treatment.